US2018043000A1PendingUtilityA1

Treatment of social anxiety disorder, obsessive compulsive disorder and panic disorder using botulinum toxin

61
Assignee: FINZI ERICPriority: Nov 12, 2013Filed: Oct 4, 2017Published: Feb 15, 2018
Est. expiryNov 12, 2033(~7.3 yrs left)· nominal 20-yr term from priority
A61P 25/00A61K 45/06A61K 31/5513A61K 38/4893C12Y 304/24069A61K 2300/00
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilii and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilii and/or a procerus muscle in the subject, thereby treating PTSD. The neurotoxin can be Botulinum toxin A, such as at a dose of about 20 to about 50 units of Botulinum toxin A.

Claims

exact text as granted — not AI-modified
1 . A method for treating a social anxiety disorder in a subject, comprising administering a therapeutically effective amount of a  Botulinum  toxin to a corrugator supercilii and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilii and/or a procerus muscle, and optionally administering the  Botulinum  toxin to the depressor anguli oris muscles of the subject, thereby treating the social anxiety disorder in the subject. 
     
     
         2 . The method of  claim 1 , wherein the  Botulinum  toxin is  Botulinum  toxin A. 
     
     
         3 . The method of  claim 1 , comprising administering the therapeutically effective amount of the neurotoxin to the corrugator supercilii and the procerus muscle. 
     
     
         4 . The method of  claim 3 , wherein the subject does not have any other psychiatric disorder. 
     
     
         5 . The method of  claim 3 , wherein the subject does not have a muscular disorder or paralysis. 
     
     
         6 . The method of  claim 3 , wherein about 20 to about 50 Unit equivalents of  Botulinum  toxin type A are administered to the corrugator supercilii and the procerus muscle in the subject. 
     
     
         7 . The method of  claim 6 , further comprising administering an additional dose of about 20 to about 50 Unit equivalents of  Botulinum  toxin type A to the corrugator supercilii and the procerus muscle after about two to six months. 
     
     
         8 . The method of  claim 3 , wherein the subject is human. 
     
     
         9 . A method for treating a social anxiety disorder, an obsessive compulsive disorder or a panic disorder in a subject, comprising
 selecting a subject with the social anxiety disorder, the obsessive compulsive disorder or the panic disorder, and   administering a therapeutically effective amount of  Botulinum  toxin A to a corrugator supercilii muscle and a procerus muscle of the subject to cause paralysis of the corrugator supercilii muscle and procerus muscle, and optionally administering the  Botulinum  toxin A to the depressor anguli oris muscles of the subject, wherein the  Botulinum  A toxin does not cross the blood brain barrier,   thereby treating the social anxiety disorder, the obsessive compulsive disorder or the panic disorder in the subject, wherein the subject does not have an underlying muscular physical condition that is treatable with  Botulinum  toxin A.   
     
     
         10 . The method of  claim 9 , wherein about 20 to about 40 Unit equivalents of  Botulinum  toxin type A are administered to the corrugator supercilii
 muscle and the procerus muscle of the subject.   
     
     
         11 . The method of  claim 9 , wherein about 29 to about 40 Unit equivalents of  Botulinum  toxin type A are administered to the corrugator supercilii muscle and the procerus muscle of the subject. 
     
     
         12 . The method of  claim 10 , further comprising administering an additional dose of about 30 to about 60 Unit equivalents of  Botulinum  toxin type A to the corrugator supercilii muscle and the procerus muscle after about two to six months. 
     
     
         13 . The method of  claim 9 , wherein the underlying muscular physical condition is torticollis. 
     
     
         14 . The method of  claim 9 , further comprising administering to the subject a therapeutically effective amount of an additional modality of treatment for the social anxiety disorder, obsessive compulsive disorder or panic disorder. 
     
     
         15 . The method of  claim 14 , wherein the additional modality of treatment comprises administration of an antidepressant, psychotherapy, a beta blocker, or behavioral therapy. 
     
     
         16 . The method of  claim 14 , wherein the subject has the obsessive compulsive disorder. 
     
     
         17 . The method of  claim 16 , wherein the additional modality of treatment comprises a selective serotonin reuptake inhibitor (SSRI), a tricyclic antidepressant, a benzodiazepine or an atypical antipsychotic. 
     
     
         18 . The method of  claim 9 , further comprising performing a psychological assessment on the subject. 
     
     
         19 . The method of  claim 9 , wherein the subject has the obsessive compulsive disorder, and wherein the method further comprising administering to the subject a therapeutically effective amount of an additional modality of treatment, wherein the additional modality of treatment comprises an antidepressant, psychotherapy, a beta blocker, or behavioral therapy. 
     
     
         20 . The method of  claim 1 , wherein the  botulinum  toxin is administered into the depressor anguli oris muscles of the subject.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.